Navigation Links
Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
Date:4/24/2013

SUNNYVALE, Calif., April 24, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three months ended March 31, 2013 after the NASDAQ Market closes on Wednesday, May 1, 2013.  The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day. As previously announced, the Company changed its fiscal year end from June 30 to December 31, effective December 31, 2012. As a result, the three months ended March 31, 2013 represents the Company's fiscal 2013 first quarter.

Conference call and webcast details:

Date: May 1, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877)-407-0778
International: (201)-689-8565

Replay Number (Toll Free): (877)-660-6853
Replay Number (International): (201)-612-7415
Conference ID #: 413317

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.
The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
2. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
3. Pharmacyclics, Inc. Prices Public Offering of Common Stock
4. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
5. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
6. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
7. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
8. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
9. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
10. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
11. Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... and Markets has announced the addition of the "Liver Cirrhosis Drugs ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... the following questions: What are the key drugs ... in the Global Liver Cirrhosis market? What are the ...
(Date:2/21/2017)... 21, 2017 Research and Markets has announced the ... report to their offering. ... The latest research Anthrax Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: What ... are they positioned in the Global Anthrax market? What ...
(Date:2/20/2017)... 20, 2017 Provides understanding and access ... into by the worlds leading healthcare companies. ... Description The Global Anemia Partnering Terms and Agreements ... partnering deals and agreements entered into by the ... in partnering deals - Top deals by ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Each February the nation ... (officially African American History Month ). This month-long celebration encourages ... diverse race of people, but also the opportunity to examine the trends of ...
(Date:2/21/2017)... ... 2017 , ... One of the most prevalent health conditions ... and financial consequences of inaction. On March 3, World Hearing Day, the American ... about their hearing. , Effective treatment in the form of hearing aids and ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... Along with ... healthy lifestyle and make small changes that can lead to a lifetime of heart ... possibility of a cardiac emergency. , The Athletic Trainers’ Society of New ...
(Date:2/20/2017)... ... 2017 , ... Nancy Johnston Toll marks her debut in the ... the Bump in the Road ” (published by Xlibris). Inspired from her personal experiences, ... the ups and downs experienced by anyone going through cancer treatment and how one ...
(Date:2/20/2017)... ... 2017 , ... Scrubbing in for his first esophageal cancer case in the ... excitement of the surgeon training him. , “He was giddy and almost couldn’t contain ... anyone, but I would do it for free,’” Dr. Pezzi recalled. “He genuinely was ...
Breaking Medicine News(10 mins):